Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

April 27, 2010

Celgene Corporation v. Cyclacel Pharmaceuticals Inc.

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. April 04, 2013

    Celgene's $5.5M Patent Buy Ends Cancer-Therapy IP Row

    Biopharmaceutical company Cyclacel Pharmaceuticals Inc. has agreed to sell four patents to rival Celgene Corp. for $5.5 million, ending federal litigation in Delaware over the validity of the patents and whether they were infringed by Celgene's cancer treatment Istodax, Cyclacel announced Thursday.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login